'''5F-SDB-006''' is a drug that acts as a potent [[agonist]] for the [[cannabinoid receptor]]s, with an EC<sub>50</sub> of 50 nM for human CB<sub>1</sub> receptors, and 123 nM for human CB<sub>2</sub> receptors.<ref>{{cite journal | url=http://pubs.acs.org/doi/abs/10.1021/acschemneuro.5b00107 | date=August 2015 | first1=S. D. | first10=M. | first11=M. | first12=I. S. | first13=M. | first2=J. | first4=A. | last5=Longworth | first5=M. | last6=Wilkinson | first6=S. M. | last1=Banister | last11=Connor | last12=McGregor | last13=Kassiou | title=Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135 | last2=Stuart | last3=Kevin | first3=R. C. | last4=Edington | last7=Beinat | first7=C. | last8=Buchanan | first8=A. S. | last9=Hibbs | first9=D. E. | journal=ACS Chemical Neuroscience | last10=Glass | volume=6 | issue=8 | pages=1445–1458 | doi=10.1021/acschemneuro.5b00107 | pmid=25921407}}</ref> It was discovered during research into the related compound [[APICA]] which had been sold illicitly as "2NE1".<ref>{{cite journal | first1=S. D. | first10=M. | first11=M. | first12=I. S. | first13=M. | journal=ACS Chemical Neuroscience | last1=Banister | last10=Glass | last11=Connor | last12=McGregor | last13=Kassiou | title=The synthesis and pharmacological evaluation of adamantane-derived indoles: Novel cannabimimetic drugs of abuse | last2=Wilkinson | first2=S. M. | last3=Longworth | first3=M. | last4=Stuart | first4=J. | last5=Apetz | first5=N. | last6=English | first6=K. | last7=Brooker | first7=L. | last8=Goebel | first8=C. | last9=Hibbs | first9=D. E. | pmc=3715837 | date=July 2013 | volume=4 | issue=7 | pages=1081–1092 | doi=10.1021/cn400035r | pmid=23551277}}</ref> 5F-SDB-006 is the terminally fluorinated analog of [[SDB-006]], just as [[STS-135 (drug)|STS-135]] is the terminally fluorinated analog of [[APICA (synthetic cannabinoid drug)|APICA]].
